ReviewAmerican journal of clinical dermatology2026
Psychocutaneous Disorders in Pediatric and Adolescent Populations: A Narrative Review.
Review in American journal of clinical dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- What's New in Photoprotection?American journal of clinical dermatology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psychocutaneous disorders (PCDs) in children and adolescents lie at the intersection of dermatology and psychiatry and include primary psychiatric conditions with cutaneous manifestations, dermatologic diseases with psychiatric sequelae, and functional or overlap syndromes. Despite substantial psychosocial burden and chronic morbidity, pediatric PCDs remain under-recognized and inconsistently managed. We conducted a narrative review of PubMed, Embase, PsycINFO, Scopus, and Web of Science (2000-2025), including epidemiologic studies, clinical trials, meta-analyses, and consensus statements addressing prevalence, risk factors, diagnostic tools, and management strategies in pediatric psychodermatology. Available data suggest that 20-30% of youth with chronic skin disease have comorbid psychiatric conditions; trichotillomania and excoriation disorder affect approximately 1-5% of children, and adolescents with acne have a two- to three-fold increased risk of depression. Diagnosis is frequently delayed due to overlapping clinical presentations, limited clinician training, and inconsistent use of validated screening instruments, many of which are better studied in older adolescents than younger children. Behavioral interventions remain first-line for most pediatric PCDs, with pharmacologic therapy reserved for moderate-to-severe or refractory cases; optimized dermatologic management may mitigate secondary psychiatric distress. Early recognition through structured screening, developmentally informed assessment, and attention to family and psychosocial context is needed to improve outcomes. Key gaps include limited pediatric-specific epidemiologic data, insufficient validation of assessment tools in younger populations, and a lack of longitudinal treatment studies, highlighting the need for targeted research to inform care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.